PharmiWeb.com - Global Pharma News & Resources
21-Jan-2019

The Recombinant Human Interferon a2b Market in China (2018-2022): Injections, Capsules and Gels Take Up a Large Market Share - ResearchAndMarkets.com

The "Investigation Report on China's Recombinant Human Interferon a2b Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering

The report estimates that by the end of 2018, more than 90 million people in China were infected with hepatitis B virus and 8 million carried hepatitis C virus.

With the increasing incidence of herpes, 80%-90% of the Chinese population are infected with herpes zoster virus, and 30% of the infected may develop chickenpox, and the rest 70% will be attacked by herpes zoster when they are weak. Furthermore, over 40% of married women in China are suffering from cervical erosion.

According to market research, the sales value of Recombinant Human Interferon a2b showed an upward trend after the drug was launched in China, reaching about CNY 271 million in 2017. The injections, capsules and gels take up a large market share, with Shanghai Huaxin High Biotechnology Inc., Zhaoke Pharmaceutical (Hefei) Co. Ltd. and Schering-Plough as the top market players by sales value.

Topics Covered

  • Status of China's Recombinant Human Interferon a2b market
  • Major manufacturers of Recombinant Human Interferon a2b in China
  • Prices of Recombinant Human Interferon a2b in China
  • Major factors influencing the development of Recombinant Human Interferon a2b in China
  • Prospect of China's Recombinant Human Interferon a2b market from 2018 to 2022

Companies Featured

  • Anhui Anke Biotechnology (Group)
  • Beijing Kawin Technology Share-Holding (Kawin Yisheng)
  • Schering-Plough (Intron A)
  • Shanghai Huaxin High Biotechnology (Xinhuanuo)
  • Tianjin Sinobioway Biomedicine (Alfaron)
  • Zhaoke Pharmaceutical (Hefei) (Yallaferon)
  • Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/2rrmg4/the_recombinant?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190121005161/en/

Editor Details

Last Updated: 21-Jan-2019